Search Results for: Clinical Roundup
-
Clinic Roundup
Muscle strength, clinical function and patient-reported outcomes also will be evaluated, though the study is not powered for those endpoints...two dose levels of active drug at four clinical sites in the U.SBioWorld Today | Wednesday, October 31, 2012 -
Clinic Roundup
Cellceutix Corp., of Beverly, Mass., said it has recruited the first patients with advanced solid tumors for clinical studies of cancer candidate KevetrinBioWorld Today | Tuesday, October 30, 2012 -
Hydrocodone Combo Products Come Under FDA Microscope
Thus, Calderon said she "would recommend requiring clinical studies to fully evaluate the abuse potential" of products submitted for review that exceed that levelBy Marie Powers | BioWorld Today | Monday, October 29, 2012 -
Clinic Roundup
Cytori Therapeutics Inc., of San Diego, said two independent investigator-sponsored and funded cell therapy clinical trials in Japan have been approved...Patients will be monitored for development of clinical symptoms and viral shedding...Initiation of the study followed a successful, dose-escalation Phase I study in which clinical activity was observed in five of seven patients receiving the two highest dose levelsBioWorld Today | Friday, October 26, 2012 -
No Bones About It: $35M Add Helps Drive Thrasos' AKI Drug
The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase improves kidney function and reduces the need for dialysis...Puma is working on neratinib, an oral, irreversible kinase inhibitor for HER2-posistive metastatic breast cancer. (See BioWorld TodayBy Randy Osborne | BioWorld Today | Friday, October 26, 2012 -
Clinic Roundup
Hadasit Bio-Holdings Ltd., of Jerusalem, said portfolio company Enlivex completed a 13-patient clinical trial of cellular treatment ApoCell for graft-vs.-host disease (GvHD), with results indicating efficacy and safety in recipients of bone marrow transplants from foreign donors...The primary endpoint of the 33-patient study is to determine the clinical benefit rate, while secondary objectives include progression-free survival and safety and tolerabilityBioWorld Today | Thursday, October 25, 2012 -
Bringing RNA Back, Mirna Gets $34.5M in Series C
Mirna will be the first company in clinical trials with a miRNA replacement therapy, and that fresh and different approach may have helped the company to attract its large, deep-pocketed investors...Shares of XOMA (NASDAQ:XOMA) fell 23 cents, to close at $2.99 Wednesday.By Catherine Shaffer | BioWorld Today | Thursday, October 25, 2012 -
Financings Roundup
The funds were raised from accredited investors and will be used to advance multiple clinical development programsBioWorld Today | Tuesday, October 23, 2012 -
Clinic Roundup
Derma Sciences Inc., of Princeton, N.J., said it plans to begin its Phase III program in December for DSC127, a clinical formulation of NorLeu3-A(1,7), in diabetic foot ulcers, to support the filing of a new drug applicationBioWorld Today | Tuesday, October 23, 2012 -
Pharma: Clinic Roundup
Investigators said 47 percent of patients receiving Simponi 50 mg and 51 percent of patients receiving Simponi 100 mg maintained clinical response through week 54 compared with 31 percent of patients on placebo (p = 0.01 and p < 0.001, respectively...Investigators will report clinical response, clinical remission and mucosal healing results through one year at the American College of Gastroenterology meeting in Las VegasBioWorld Today | Tuesday, October 23, 2012 -
Cat on a Hot Twin Proof? After Cougar, Puma Roars
The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.By Randy Osborne | BioWorld Today | Monday, October 22, 2012 -
Financings Roundup
Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities...Net proceeds are expected to total $19.3 million and will be used for ongoing clinical development of dendritic cell-based vaccine ICT-107 and for general corporate purposesBioWorld Today | Friday, October 19, 2012 -
Pharma: Clinic Roundup
Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase IIb study testing Stelara (ustekinumab) in moderate to severe Crohn's disease showed that, among patients who had previously failed or were intolerant to at least one tumor necrosis factor antagonist, a significantly greater proportion receiving intravenous Stelara achieved the primary endpoint of clinical response at week six, defined as a 100-point reduction in Crohn's Disease Activity IndexBioWorld Today | Friday, October 19, 2012 -
Clinic Roundup
The study showed that the drug was safe and well tolerated at all dose levels, and that more patients in the higher-dose cohorts showed improvement in their clinical disease activity index than patients in the lower-dose or placebo cohortsBioWorld Today | Friday, October 19, 2012 -
Cebix Closes $30.9M Series B, Reports Phase II Ersatta Data
The investors were very enthusiastic about the results from the Phase I/II clinical trial...APIM Therapeutics A/S, of Trondheim, Norway, closed a financing round to fund ATX-101, its lead compound, toward clinical trials...Proceeds would be used for R&D activities, clinical trials, investment in capital equipment and for working capital and other general corporate purposesBy Catherine Shaffer | BioWorld Today | Thursday, October 18, 2012 -
Clinic Roundup
Biogen Idec Inc., of Weston, Mass., reported data from studies testing oral BG-12 (dimethyl fumarate) at the European Committee for the Treatment and Research of Multiple Sclerosis meeting in Lyon, France, supporting clinical and radiological effects of the drug in people with relapsing-remitting multiple sclerosis (MSBioWorld Today | Monday, October 15, 2012 -
Clinic Roundup
StemCells Inc., of Newark, Calif., said two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the company's HuCNS-SC cells (purified human neural stem cells) for a range of myelination disorders were published in the Oct. 10, 2012, edition of Science Translational MedicineBioWorld Today | Friday, October 12, 2012 -
Kythera, Intercept Dazzle with Dueling Initial Public Offerings
Intercept estimated that remaining clinical development for OCA for PBC will take about $40 million, and that the current offering, plus $29.8 million from its recent Series C financing, plus its cash will be enough to put it over the top. (See BioWorld Today, Sept. 6, 2012.) That clinical development includes completion of the POISE trial and initiation of its long-term safety extension, initiation of a Phase III outcomes trial, carcinogenicity studies in animals, a Phase I safety trial inBy Catherine Shaffer | BioWorld Today | Friday, October 12, 2012 -
Clinic Roundup
Canyon Pharmaceuticals Inc., of Parsippany, N.J., said results from its open-label, single-arm study, dubbed DESIR-ABLE, showed that desirudin (Revasc, Iprivask) demonstrated clinical utility and safety for the prevention of dangerous blood clots in a broad population of surgical and medically ill patients...Results were published in Clinical and Applied Thrombosis and HemostasisBioWorld Today | Thursday, October 11, 2012 -
'Gates' Swing Open to $30M in Genocea Series C Funding
Guinea pigs showed a 45 percent reduction in duration, and a 55 percent reduction in severity, of clinical symptoms...A clinical program is slated to start next year, and GEN-004 "potentially can be taken in directions that cover new diseases," since the bug that causes pneumonia is responsible for other illnesses as well...LoneStar Heart Inc., of San Francisco, completed a milestone-based equity financing worth up to $20 million to support the clinical testing and regulatory clearance of its leadBy Randy Osborne | BioWorld Today | Thursday, October 11, 2012
Category
Related Keywords
Categories
- x BioWorld Today (2573)
- x BioWorld International (51)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.